CIK 0001501796 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Aura Biosciences, Inc.
Sign in to watch- Ticker
- AURA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320271970
- Phone
- (617)500-8864
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-21 | Elazzouzi Amy Vice President, Finance | Sale | −1,001 | $7.67 | $8K | 38,442 |
| 2024-11-18 | Hopkins Janet Jill Chief Medical Officer | Sale | −11,822 | $9.36 | $111K | 151,693 |
| 2024-10-29 | de los Pinos Elisabet See Remarks | Sale | −9,200 | $10.74 | $99K | 320,647 |
| 2024-10-29 | Elazzouzi Amy Vice President, Finance | Sale | −553 | $10.74 | $6K | 39,443 |
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise 10b5-1 | +17,500 | $2.74 | $48K | 151,776 |
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise 10b5-1 | +2,631 | $4.25 | $11K | 154,407 |
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise 10b5-1 | +5,000 | $5.48 | $27K | 159,407 |
| 2024-10-18 | Feder Julie B Chief Financial Officer | Sale 10b5-1 | −25,131 | $12.03 | $302K | 134,276 |
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,500 | 68,257 | ||
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,631 | 32,359 | ||
| 2024-10-18 | Feder Julie B Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 120,547 | ||
| 2024-10-18 | de los Pinos Elisabet See Remarks | Option exercise 10b5-1 | +24,992 | $2.74 | $68K | 354,839 |
| 2024-10-18 | de los Pinos Elisabet See Remarks | Sale 10b5-1 | −24,992 | $12.04 | $301K | 329,847 |
| 2024-10-18 | de los Pinos Elisabet See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,992 | 336,171 | ||
| 2024-10-16 | Plavsic Mark Chief Technology Officer | Sale | −7,383 | $9.85 | $73K | 121,132 |
| 2024-09-27 | de los Pinos Elisabet See Remarks | Option exercise | +5,474 | $5.76 | $32K | 329,847 |
| 2024-09-27 | de los Pinos Elisabet See Remarks | Option exercise · Stock Option (Right to Buy) | −5,474 | 0 | ||
| 2024-06-20 | Mattessich Antony C. Director | Grant or award | +10,500 | 10,500 | ||
| 2024-06-20 | Mattessich Antony C. Director | Grant or award · Stock Option (Right to Buy) | +14,500 | 14,500 | ||
| 2024-06-20 | Srivastava Sapna Director | Grant or award | +10,500 | 10,500 |
Page 6 of 11 · 219 trades